PDCD1 and non-small cell lung carcinoma: Wankhede et al. analyzed 12 randomized controlled studies and found that compared to chemotherapy, PD-1/PD-L1 inhibitor-chemotherapy combination regimens were more likely to achieve objective response in NSCLC patients (Wankhede et al., 2023).